{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:57:57Z","timestamp":1789595877983,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T00:00:00Z","timestamp":1554681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T00:00:00Z","timestamp":1554681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2019,5,1]]},"DOI":"10.1007\/s40263-019-00626-2","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T08:03:37Z","timestamp":1554710617000},"page":"513-522","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females"],"prefix":"10.1007","volume":"33","author":[{"given":"Yang","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osaro","family":"Eisele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apinya","family":"Vutikullird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Mikol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,8]]},"reference":[{"key":"626_CR1","doi-asserted-by":"publisher","DOI":"10.1177\/106002801983516","author":"SG Garland","year":"2019","unstructured":"Garland SG, Smith SM, Gums JG. Erenumab: a first-in-class monoclonal antibody for migraine prevention. Ann Pharmacother. 2019. \n                  https:\/\/doi.org\/10.1177\/106002801983516\n                  \n                .","journal-title":"Ann Pharmacother"},{"key":"626_CR2","unstructured":"Amgen Inc.\u00a0Aimovig\u2122 (erenumab-aooe) US prescribing information. 2018.\u00a0\n                  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761077s000lbl.pdf\n                  \n                . Accessed 8 June 2018."},{"key":"626_CR3","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1177\/0333102409355601","volume":"30","author":"TW Victor","year":"2010","unstructured":"Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia Int J Headache. 2010;30:1065\u201372.","journal-title":"Cephalalgia Int J Headache."},{"key":"626_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1177\/2042098614548857","volume":"5","author":"J Brynhildsen","year":"2014","unstructured":"Brynhildsen J. Combined hormonal contraceptives: prescribing patterns, compliance, and benefits versus risks. Ther Adv Drug Saf. 2014;5:201\u201313.","journal-title":"Ther Adv Drug Saf"},{"issue":"Suppl 1","key":"626_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/13697130500148875","volume":"8","author":"H Kuhl","year":"2005","unstructured":"Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climact J Int Menopause Soc. 2005;8(Suppl 1):3\u201363.","journal-title":"Climact J Int Menopause Soc"},{"key":"626_CR6","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.contraception.2012.12.011","volume":"87","author":"FZ Stanczyk","year":"2013","unstructured":"Stanczyk FZ, Archer DF, Bhavnani BR. Ethinyl estradiol and 17beta-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. Contraception. 2013;87:706\u201327.","journal-title":"Contraception."},{"key":"626_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0010-7824(02)00473-0","volume":"67","author":"GL Hammond","year":"2003","unstructured":"Hammond GL, Abrams LS, Creasy GW, Natarajan J, Allen JG, Siiteri PK. Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties. Contraception. 2003;67:93\u20139.","journal-title":"Contraception."},{"key":"626_CR8","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1007\/s11095-017-2183-6","volume":"34","author":"T Vu","year":"2017","unstructured":"Vu T, Ma P, Chen JS, et al. Pharmacokinetic-pharmacodynamic relationship of erenumab (AMG 334) and capsaicin-induced dermal blood flow in healthy and migraine subjects. Pharm Res. 2017;34:1784\u201395.","journal-title":"Pharm Res"},{"key":"626_CR9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/106002808602000504","volume":"20","author":"PF D\u2019Arcy","year":"1986","unstructured":"D\u2019Arcy PF. Drug interactions with oral contraceptives. Drug Intell Clin Pharm. 1986;20:353\u201362.","journal-title":"Drug Intell Clin Pharm"},{"issue":"31","key":"626_CR10","first-page":"139","volume":"2005","author":"Faculty of Family P and Reproductive Health Care Clinical Effectiveness U. FFPRHC Guidance","year":"2005","unstructured":"Faculty of Family P and Reproductive Health Care Clinical Effectiveness U. FFPRHC Guidance. Drug interactions with hormonal contraception. J Fam Plan Reprod Health Care. 2005;2005(31):139\u201351.","journal-title":"J Fam Plan Reprod Health Care."},{"key":"626_CR11","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1111\/j.1463-1326.2012.01635.x","volume":"14","author":"VV Upreti","year":"2012","unstructured":"Upreti VV, Hsiang CB, Li L, Xu X, LaCreta FP, Boulton DW. Effect of saxagliptin on the pharmacokinetics of the active components of Ortho-Cyclen((R)), a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women. Diabetes Obes Metab. 2012;14:1155\u20137.","journal-title":"Diabetes Obes Metab"},{"key":"626_CR12","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1177\/0091270007306958","volume":"47","author":"K Seitz","year":"2007","unstructured":"Seitz K, Zhou H. Pharmacokinetic drug\u2013drug interaction potentials for therapeutic monoclonal antibodies: reality check. J Clin Pharmacol. 2007;47:1104\u201318.","journal-title":"J Clin Pharmacol"},{"key":"626_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5414\/CP201951","volume":"52","author":"X Zhang","year":"2014","unstructured":"Zhang X, Rowell L, Fettner S, Lau C, Teuber D. Assessment of disease\u2013drug\u2013drug interaction between single-dose tocilizumab and oral contraceptives in women with active rheumatoid arthritis. Int J Clin Pharmacol Ther. 2014;52:27\u201338.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"626_CR14","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1111\/j.0013-9580.2003.06203.x","volume":"44","author":"SC Nallani","year":"2003","unstructured":"Nallani SC, Glauser TA, Hariparsad N, et al. Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate. Epilepsia. 2003;44:1521\u20138.","journal-title":"Epilepsia."},{"key":"626_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1528-1157.1997.tb01123.x","volume":"38","author":"WE Rosenfeld","year":"1997","unstructured":"Rosenfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia. 1997;38:317\u201323.","journal-title":"Epilepsia."},{"key":"626_CR16","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1046\/j.1528-1157.2003.55602.x","volume":"44","author":"DR Doose","year":"2003","unstructured":"Doose DR, Wang SS, Padmanabhan M, Schwabe S, Jacobs D, Bialer M. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia. 2003;44:540\u20139.","journal-title":"Epilepsia."},{"key":"626_CR17","volume-title":"Endotext","author":"BG Reed","year":"2000","unstructured":"Reed BG, Carr BR. The normal menstrual cycle and the control of ovulation. In: De Groot LJ, Chrousos G, Dungan K, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc; 2000."}],"updated-by":[{"DOI":"10.1007\/s40263-019-00638-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T00:00:00Z","timestamp":1557100800000}}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00626-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-019-00626-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00626-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T02:22:04Z","timestamp":1604110924000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-019-00626-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,8]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5,1]]}},"alternative-id":["626"],"URL":"https:\/\/doi.org\/10.1007\/s40263-019-00626-2","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40263-019-00638-y","asserted-by":"object"}]},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,8]]},"assertion":[{"value":"8 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2019","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors would like to correct the error in the publication of the original article. The correction detail is given below:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The Open Access Article Processing Charge was funded by Amgen Inc. This study was fully funded by Amgen Inc. Erenumab is co-developed in partnership with Amgen Inc. and Novartis. Jon Nilsen, PhD (Amgen Inc.) provided medical writing support for this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yang Xu, Kristin Gabriel, Yi Wang, Yanchen Zhou, Osaro Eisele, Daniel D. Mikol, and Edward Lee are or were employees and stockholders of Amgen Inc. at the time of the study. Apinya Vutikullird is an employee of WCCT Global, which received research funding for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Institutional Review Boards at each center approved the study protocol. Sites maintained compliance with the Health Insurance Portability and Accountability Act or relevant regional regulations. The study was conducted in accordance with the ethical principles of the International Conference on Harmonisation Good Clinical Practice Guidelines (ICH GCP) and the Helsinki Declaration of 1975 (as revised in 2008).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}